Get the Stockscreener App
0.8873
2.80%
-0.0256
After Hours:
.87
-0.0173
-1.95%
Standard Biotools Inc stock is traded at $0.8873, with a volume of 3.36M.
It is down -2.80% in the last 24 hours and down -22.84% over the past month.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
See More
Previous Close:
$0.9129
Open:
$0.925
24h Volume:
3.36M
Relative Volume:
0.92
Market Cap:
$347.35M
Revenue:
$86.26M
Net Income/Loss:
$-50.08M
P/E Ratio:
-3.6231
EPS:
-0.2449
Net Cash Flow:
$-94.48M
1W Performance:
+18.72%
1M Performance:
-22.84%
6M Performance:
-30.13%
1Y Performance:
-34.27%
1-Day Range:
$0.8771
$0.94
1-Week Range:
$0.7399
$0.94
52-Week Range:
$0.7029
$1.72
Standard Biotools Inc Stock (LAB) Company Profile
Name
Standard Biotools Inc
Sector
Industry
Phone
(650) 266-6000
Address
50 MILK STREET, BOSTON
Compare LAB vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LAB
Standard Biotools Inc
|
0.8873 | 322.06M | 86.26M | -50.08M | -94.48M | -0.2449 |
ABT
Abbott Laboratories
|
95.63 | 158.05B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
324.73 | 120.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.06 | 100.14B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.60 | 63.44B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
95.18 | 52.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Standard Biotools Inc Stock (LAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Downgrade | TD Cowen | Buy → Hold |
| Feb-27-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Apr-16-24 | Initiated | TD Cowen | Buy |
| Apr-04-24 | Initiated | Jefferies | Buy |
| Jul-12-23 | Initiated | KeyBanc Capital Markets | Overweight |
Standard Biotools Inc Stock (LAB) Latest News
Enterprise value to revenue forward of Standard BioTools Inc. – NASDAQ:LAB - TradingView
Price to earnings forward of Standard BioTools Inc. – BOATS:LAB - TradingView
Enterprise value to EBITDA forward of Standard BioTools Inc. – NASDAQ:LAB - TradingView
Price to book forward of Standard BioTools Inc. – NASDAQ:LAB - TradingView
Price to sales forward of Standard BioTools Inc. – BOATS:LAB - TradingView
Form 4 Standard Biotools Inc For: 23 June - Investing.com UK
Form 4 Standard Biotools Inc For: 23 June By Investing.com - Investing.com Australia
Standard BioTools (LAB) director receives new RSU and stock option awards - Stock Titan
Standard BioTools (LAB) awards 500,000 RSUs to chief business officer - Stock Titan
STANDARD BIOTOOLS (LAB) director Frank Witney receives new RSU and stock option awards - Stock Titan
Eli Casdin (LAB) granted RSUs and stock options, reports large fund holdings - Stock Titan
STANDARD BIOTOOLS (NASDAQ: LAB) director receives new RSU and stock option awards - Stock Titan
STANDARD BIOTOOLS (NASDAQ: LAB) director awarded RSUs and stock options in new Form 4 - Stock Titan
Tranche Update on Standard BioTools Inc.'s Equity Buyback Plan announced on March 1, 2024. - marketscreener.com
Standard BioTools Inc (LAB) Institutional Confidence - TradingKey
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AstroNova, Inc. (Nasdaq – ALOT), Open Lending Corporation (Nasdaq – LPRO), Huntsman Corporation (NYSE – HUN), Standard BioTools Inc. (Nasdaq – LAB - The Malone Telegram
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AstroNova, Inc. (Nasdaq – ALOT), Open Lending Corporation (Nasdaq – LPRO), Huntsman Corporation (NYSE – HUN), Standard BioTools Inc. (Nasdaq – LAB) - GlobeNewswire Inc.
Standard BioTools Shareholders Approve 2026 Equity Incentive Plans - TipRanks
Standard BioTools (LAB) investors approve 2026 equity plan and ESPP share increase - Stock Titan
Standard BioTools Inc (LAB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Standard BioTools Inc (LAB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Standard BioTools Inc (LAB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Standard BioTools Inc (LAB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Standard BioTools Inc (LAB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Standard BioTools Inc (LAB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Standard BioTools Inc (LAB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Standard BioTools Inc (LAB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Standard BioTools (LAB) Slides 3.65% as Biotech Sector Faces HeadwindsNAAIM Leverage - newsline.com
Are ROKU, PAYO, LAB, FOX Obtaining Fair Deals for their Shareholders? - TradingView
LAB Stock Alert: Halper Sadeh LLC is Investigating Whether Standard BioTools Inc. is Obtaining a Fair Price for its Shareholders - The Daily Tribune News
Viking backs Standard BioTools (LAB) merger with Treeline Biosciences - Stock Titan
Casdin funds deepen tie to Standard BioTools (LAB) with 23.9% stake and Treeline merger support - Stock Titan
Company that shut down Peninsula HQ now swept up in reverse merger - The Business Journals
Crude Oil Gains Over 1%; Motorcar Parts Of America Shares Surge After Q4 Earnings - Sahm
Stealthy startup Treeline plans a reverse merger - BioPharma Dive
Standard BioTools to merge with Treeline in biotech transformation deal - The Pharma Letter
Standard BioTools Inc. (LAB) Discusses Merger and Strategic RationaleSlideshow (NASDAQ:LAB) 2026-06-08 - Seeking Alpha
Standard BioTools (LAB) Plunges Over 30%, Testing Critical Support at $0.76Put Dominated - lwvtexas.org
Standard BioTools and Treeline Biosciences anno... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
Standard BioTools and Treeline Biosciences Announce $900M Merger to Form Public Biopharma Company Focused on Oncology and Precision Medicines 12 - Minichart
Standard BioTools to Merge with Treeline Biosciences - TipRanks
Standard BioTools (NASDAQ: LAB) to merge with Treeline in $2.5B exchange‑ratio deal - Stock Titan
Standard BioTools to Merge With Treeline in All-Stock Deal Valuing Treeline at $2.5 Billion - TradingView
Treeline Biosciences, Standard BioTools (NASDAQ: LAB) plan all-stock merger - Stock Titan
Standard BioTools and Treeline Biosciences Agree to Merger, Creating Well-Funded Clinical-Stage Biopharma Company - citybiz
Standard BioTools, Treeline Biosciences to Merge in All-Stock Deal - marketscreener.com
Standard BioTools to merge with Treeline Biosciences By Investing.com - Investing.com Nigeria
Standard BioTools to merge with Treeline Biosciences - Investing.com
$900M cancer drug pipeline: Treeline, Standard BioTools to merge - Stock Titan
Standard BioTools Regains Compliance With Nasdaq's Minimum Bid Price Requirement - marketscreener.com
Fenwick Represents Treeline Biosciences in Definitive Merger Agreement with Standard BioTools - fenwick.com
Standard Biotools Inc Stock (LAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Standard Biotools Inc Stock (LAB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kim Hanjoon Alex | Chief Financial Officer |
Apr 06 '26 |
Option Exercise |
0.00 |
70,183 |
0 |
2,800,702 |
| Casdin Partners Master Fund, L | Director |
Dec 04 '25 |
Buy |
1.45 |
150,000 |
217,020 |
72,100,000 |
| Casdin Partners Master Fund, L | Director |
Dec 02 '25 |
Buy |
1.42 |
125,000 |
177,512 |
71,875,000 |
| Casdin Partners Master Fund, L | Director |
Dec 03 '25 |
Buy |
1.44 |
75,000 |
108,037 |
71,950,000 |
| Casdin Partners Master Fund, L | Director |
Nov 25 '25 |
Buy |
1.30 |
7,550,000 |
9,838,405 |
71,750,000 |
| Casdin Partners Master Fund, L | Director |
Nov 24 '25 |
Buy |
1.43 |
150,000 |
214,875 |
64,200,000 |
| Casdin Partners Master Fund, L | Director |
Nov 20 '25 |
Buy |
1.30 |
450,000 |
586,260 |
64,050,000 |
| Casdin Partners Master Fund, L | Director |
Nov 19 '25 |
Buy |
1.28 |
350,000 |
448,910 |
63,600,000 |
| Casdin Partners Master Fund, L | Director |
Nov 18 '25 |
Buy |
1.23 |
275,000 |
339,405 |
63,250,000 |
| Casdin Partners Master Fund, L | Director |
Nov 13 '25 |
Buy |
1.20 |
450,000 |
541,395 |
62,500,000 |
2.62%
2.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):